EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Treatment Options For EGFR Mutation-Positive NSCLC

The Relationship Between EGFR Mutations and CNS Involvement

Challenges With EGFR Mutation-Positive NSCLC With CNS Involvement

Challenges With Brain Metastases

Cognitive Effects of WBRT

Challenges With Leptomeningeal Disease

Retrospective Analysis of Erlotinib and Gefitinib Activity in the CNS

Gefitinib

Erlotinib

Pulse Dosing With Erlotinib

Afatinib

Subgroup Analysis From LUX-Lung 3 and LUX-Lung 6 Trials

Osimertinib

CNS Data From AURA 3

Leptomeningeal Disease Data From BLOOM

CNS Data From FLAURA

Emerging Agents

Where to Start: TKI or Radiotherapy?

What Is the Role of Stereotactic Radiosurgery?

The Evolution of Practice

Concluding Remarks

Abbreviations

Abbreviations (cont)